Disappointment as Cancer Patients Left Waiting for Life-Saving Medicines
Rare Cancers Australia (RCA) has voiced deep disappointment following the Pharmaceutical Benefits Advisory Committee’s (PBAC) decision to reject a proposed streamlined approach to accessing the PD-1/PD-L1 inhibitor class of cancer medicines. These life-saving therapies, widely acknowledged for their effectiveness, remain difficult to access for many Australian cancer patients. Christine Cockburn, CEO of RCA, expressed frustration […]